Blue light transurethral resection and biopsy of bladder cancer with hexaminolevulinate: Histopathological characteristics and recurrence rates in a single UK centre study.
HexVix
TURBT
bladder tumour
blue light cystoscopy
carcinoma in situ
hexaminolevulinate
Journal
BJUI compass
ISSN: 2688-4526
Titre abrégé: BJUI Compass
Pays: United States
ID NLM: 101764975
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
24
09
2022
revised:
10
04
2023
accepted:
16
04
2023
medline:
28
8
2023
pubmed:
28
8
2023
entrez:
28
8
2023
Statut:
epublish
Résumé
Blue light cystoscopy with hexaminolevulinate (HAL) during transurethral resection of bladder cancer (TURBT) has been shown to improve detection, thereby reducing bladder cancer recurrence compared with white light cystoscopy. Single-centred UK (United Kingdom) study on 101 patients who underwent blue light cystoscopy between July 2017 and November 2020, performed by a single surgeon. Our study was divided into two arms; the primary arm had no prior diagnosis of bladder malignancy ( Of 98 patients, 39 had malignancy in their first blue light TURBT/biopsy: primary arm (10/41, 24.4%) and secondary arm (29/57, 50.9%), with detrusor present in 80.5% and 80.7%, respectively. In the secondary arm, blue light re-resection TURBT detected significantly more CIS (20.7% vs 51.7%, Our data confirm that blue light TURBT with HAL provides superior detection and diagnosis of CIS in patients with previous white light cystoscopy.
Identifiants
pubmed: 37636209
doi: 10.1002/bco2.250
pii: BCO2250
pmc: PMC10447208
doi:
Types de publication
Journal Article
Langues
eng
Pagination
568-574Informations de copyright
© 2023 The Authors. BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company.
Déclaration de conflit d'intérêts
I have no disclosures. I have also confirmed with all my co‐authors, who have no disclosures or conflict of interests.
Références
Cochrane Database Syst Rev. 2021 Dec 1;12:CD013776
pubmed: 34850382
Cancer. 2013 Sep 1;119(17):3219-27
pubmed: 23737352
Urol Clin North Am. 2005 May;32(2):157-64
pubmed: 15862613
Bladder Cancer. 2016 Apr 27;2(2):273-278
pubmed: 27376146
BJU Int. 2021 Jan;127(1):108-113
pubmed: 32648957
Eur Urol. 2021 Jan;79(1):82-104
pubmed: 32360052
J Urol. 1999 Jul;162(1):74-6
pubmed: 10379743
BJU Int. 2013 Dec;112(8):1096-104
pubmed: 24053153
Eur Urol Open Sci. 2021 Jul 22;31:17-27
pubmed: 34467237
Health Technol Assess. 2022 Oct;26(40):1-144
pubmed: 36300825
Eur Urol. 2013 Nov;64(5):846-54
pubmed: 23602406
J Urol. 2006 Apr;175(4):1262-7; discussion 1267
pubmed: 16515975
Eur Urol. 2023 Mar;83(3):193-194
pubmed: 36473782
Eur Urol. 2021 Apr;79(4):480-488
pubmed: 33419683
Can Urol Assoc J. 2010 Feb;4(1):56-64
pubmed: 20165581
Eur Urol. 2016 Jul;70(1):106-119
pubmed: 26996659